OncoMatch/Clinical Trials/NCT06827717
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Is NCT06827717 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies irinotecan liposome (II) + temozolomide + fluzoparib for ewing sarcoma.
Treatment: irinotecan liposome (II) + temozolomide + fluzoparib — The current study is an investigator-initiated, single-arm phase 2 study that enrolled patients with recurrent and/or metastatic Ewing sarcoma for the treatment of Irinotecan Liposome (II) Combined with Temozolomide and Fluzoparib as the second-line treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Sarcoma
Disease stage
Required: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: VAC/IE chemotherapy — first-line
first-line chemotherapy (VAC/IE) has failed, leading to distant metastasis
Cannot have received: PARP inhibitor (fluzoparib)
Previous treatment with PARP inhibitors, including but not limited to fluzoparib
Cannot have received: topoisomerase I inhibitor (irinotecan)
Previous treatment with irinotecan
Cannot have received: alkylating agent (temozolomide)
Previous treatment with temozolomide
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L; Neutrophil count ≥ 1.5 × 10^9/L; Platelet count ≥ 75 × 10^9/L
Kidney function
Creatinine ≤ 1.5x ULN or Cr clearance > 50 mL/min
Liver function
ALT and AST ≤ 2.5x ULN; TBIL ≤ 1.5x ULN
Cardiac function
LVEF ≥ 60%
Basic normal function of major organs... see protocol for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06827717 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, topoisomerase I inhibitor, alkylating agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages